About the THRIVE-2 Study
About the THRIVE-2 Clinical Study
Viridian Therapeutics is developing VRDN-001 as a potential new treatment for people living with TED. VRDN-001 is an investigational study drug that can be used only in the setting of a clinical study.
THRIVE-2
THRIVE-2 is an ongoing Phase 3 clinical study of VRDN-001 as a potential treatment for people who have been diagnosed with moderate to severe chronic TED and began experiencing symptoms more than 15 months ago.